Our Pipeline
Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.
Oncology-Focused Pipeline with Multiple Clinical Candidates
Cabiralizumab (FPA008)
CSF-1R antibody
Pancreatic cancer (Combination with Opdivo® and chemo)
Multiple tumor settings (Combination with Opdivo®)
Multiple tumor settings in ADVISE trial (Combination with Opdivo®)
Pigmented villondular synovitus (PVNS)
Bemarituzumab (FPA144)
FGFR2b antibody
FIGHT Phase 1/3 trial (with chemo) in gastric/GEJ cancer
FPA150
B7-H4 antibody
Multiple tumor settings
FPT155
CD80-Fc
Multiple tumor settings
BMS-986258
TIM-3 antibody
Phase 1/2 trial in multiple tumor settings
Multiple tumor settings
Multiple tumor settings
